drugset / Trial / NCT02922764
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed.
Timeline
- Start
- 2016-11-01
- Primary completion
- 2025-01-22
- Completion
- 2025-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abequolixron | Small molecule | 120 mg | Oral |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Pemetrexed | Small molecule | — | — |